Advertisements


We are Sorry, This Page doesn't Exist


Roche"s Tecentriq Met Primary Goal in First-Line NSCLC Study

Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS). Roche H.....»»

Category: dealsSource: nytJul 19th, 2018

Brainstorm Health: Puerto Rico Maria Deaths, Roche Lung Cancer Drug, Planned Parenthood Setback

Brainstorm Health Daily: May 29, 2018 Hurricane season does not officially begin until Friday, June 1--though that start date is somewhat artificial as Subtropical Storm Alberto made clear yesterday--driving its way across .....»»

Category: europeSource: fortuneMay 29th, 2018

Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer. Exelixis, Inc. EXEL along with its French partner, Ipse.....»»

Category: worldSource: nytDec 6th, 2018

Bristol-Myers Squibb shares decline on failed lung-cancer drug study

Bristol-Myers Squibb Co. shares declined in the extended session Monday after the drug maker said a lung-cancer treatment.....»»

Category: topSource: marketwatchNov 26th, 2018

Roche Announces Positive Data on Breast Cancer Drug Kadcyla

Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal. Roche RHHBY announced encouraging results from a phase III st.....»»

Category: smallbizSource: nytOct 16th, 2018

Roche Holding Ltd (RHHBY) Management on Virtual Pipeline Event 2018 World Conference on Lung Cancer Conference Call (Transcript)

Roche Holding Ltd (RHHBY) Management on Virtual Pipeline Event 2018 World Conference on Lung Cancer Conference Call (Transcript).....»»

Category: topSource: seekingalphaSep 26th, 2018

Roche Presentation At The IASLC World Conference On Lung Cancer, Sept. 25 2018

Roche Presentation At The IASLC World Conference On Lung Cancer, Sept. 25 2018.....»»

Category: topSource: seekingalphaSep 26th, 2018

Biopharmaceutical company fined for misleading investors

A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a lung cancer drug under development before raising $300 million in a public stock offering......»»

Category: topSource: foxnewsSep 19th, 2018

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges of misleading investors about the company‚Äôs developmental lung cancer drug......»»

Category: blogSource: 247wallstSep 19th, 2018

Bristol-Myers" Opdivo Gets FDA Nod for Small Cell Lung Cancer

Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cance.....»»

Category: topSource: zacksAug 20th, 2018

Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer

Bristol-Myers Squibb Co. said Friday the U.S. Food and Drug Admi.....»»

Category: topSource: marketwatchAug 17th, 2018

Roche Hiked Cancer Drug Price Before Empty Promise To Keep Flat

Swiss drugma.....»»

Category: blogSource: zerohedgeJul 21st, 2018

Bristol-Myers Posts Data on Empliciti, China Approves Opdivo

Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer. Br.....»»

Category: dealsSource: nytJun 18th, 2018

Lung Cancer Drug From Merck Solidifies Lead in Crowded Field - Bloomberg

KDALLung Cancer Drug From Merck Solidifies Lead in Crowded FieldBloombergIn the race to.....»»

Category: topSource: googlenewsJun 3rd, 2018

Pfizer"s Xalkori Gets Breakthrough Status for New Indications

Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications. Pfi.....»»

Category: dealsSource: nytMay 30th, 2018

Roche Won"t Go Down Without A Fight In The Front-Line Lung Cancer Space

Roche Won"t Go Down Without A Fight In The Front-Line Lung Cancer Space.....»»

Category: topSource: seekingalphaMay 30th, 2018

Roche"s Tecentriq Study Meets Co-Primary Endpoints for NSCLC

Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer. Roche RHHBY announced that the phase III study, IMpower130 on immunot.....»»

Category: smallbizSource: nytMay 29th, 2018

AstraZeneca"s drug extending survival rate in lung cancer patients

Using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity.....»»

Category: topSource: business-standardMay 26th, 2018

No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says

Treating breast-cancer patients with an expensive Roche drug for six months instead of 12 reduced heart-related side effects without sacrificing effectiveness, a new study found......»»

Category: smallbizSource: wsjMay 16th, 2018

Exelixis, Roche slide after colon cancer drug fails to meet primary study goal

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2018